It is presently unknown whether LSCs in AML and CML rely on IDO1 expression as an immune evasion strategy and whether patients with hematological malignancies may benefit from therapy with IDO1-targeting small-molecule inhibitors. Here, IDO1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.